

University of California Los Angeles to collaborate with Genetic Signatures on transformative molecular platform technology

Sydney, Australia, 6 November 2015: Molecular diagnostics company Genetic Signatures (ASX: GSS) today announced a collaboration with Dr. Scott Binder MD and his Microbiology team at the University of California, Los Angeles (UCLA) to analyze molecular testing methods for bacteria, viruses and parasites as compared to traditional testing in an effort to reduce the spread of infection in the US healthcare system.

“Better, more affordable diagnostic tools play an important role in infection prevention and anti-microbial stewardship,” said Mr. Pat Noland, Executive Vice President Genetic Signatures US. “UCLA is the ideal partner with the highest levels of scientific credibility to identify the areas where new technology can greatly enhance patient care.”

“Quick and accurate identification of co-infections including pathogens that are difficult to detect, such as *D. fragilis*, are vital in improving outcomes,” said Genetic Signatures’ Chief Executive Officer, John Melki PhD. “Broad pathogen detection improves targeted use of anti-microbial treatment, patient triage and reduced average length of stay (ALOS).”

UCLA Senior Vice Chair and Director, Pathology and Lab Medicine Clinical Services, Scott W. Binder MD added, “We look forward to working with the world-class team assembled by Genetic Signatures as we continually pursue the application of modern science and its benefit to global health.”

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Company	Media and Investor Relations
John Melki Chief Executive Officer john@geneticsignatures.com T: +61 2 9870 7580	Peter Taylor Investor Relations peter@nwrcommunications.com.au T: +61 412 036 231

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3Base™**. Founded in 2001 by the late Dr Geoffrey Grigg, the former Chief of Molecular Biology at CSIRO, Genetic Signatures has released a suite of real-time Polymerase Chain Reaction (PCR)

based products for the routine detection of infectious diseases under the **EasyScreen™** brand. MDx is a modern technique increasingly used by hospitals and pathology laboratories to detect specific sequences of the genome, the DNA or RNA that define an organism. Genetic Signatures' proprietary MDx **3Base™** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening. As the spread of infectious diseases around the world continues to grow, the Company plans to launch additional products for the detection of pathogens associated with MRSA, sexual health infections, tuberculosis and meningitis.